Modelling, Extrapolation and Simulation approaches for rare diseases - Review of two case-studies in the INVENTS project
Comets, E.; Ursino, M.; INVENTS WP 1.1 group,
Show abstract
AO_SCPLOWBSTRACTC_SCPLOWO_ST_ABSObjectiveC_ST_ABSThe objective of this work was to review the modelling and simulation methods used in two selected case-studies from the Invents project, with a focus on longitudinal data modelling, simulation methods and extrapolation approaches (across populations, across indications or across similar drugs) applied during the later phases of drug development. MethodsWe included publications based on relevance to the case-studies involved in Invents, extending the search to articles reporting results of modelling, simulation, or extrapolation approaches for the two drugs secukinumab and tocilizumab through keyword-based literature searches. ResultsWhen outcomes were measured repeatedly during the study, the focus of the analyses was usually along the lines of improvement at a given time-point, with other time-points included in secondary analyses. When PK (pharmacokinetic) or PK/PD (pharmacodynamic) models were developed, they were generally simple, with compartmental models for PK and direct or indirect response models for PD. Clinical questions addressed in the studies selected in this review were mainly centered on efficacy (57%, including exposure-response relationships and efficacy concerning patient-reported outcomes) and safety (34%). Besides the few studies investigating PK, other clinical questions focused on finding predictors of response, either biomarkers related to changes in the outcome under study, molecular characteristics of certain groups of patients, or prognostic factors at baseline. Finally, a couple of studies were more methodological. We found almost no paediatric study, despite modelling and simulation analyses being put forward in the Paediatric Investigation Plan, which could be due to the time needed to perform these studies, lack of interest in obtaining paediatric approval, waivers or failure to publish. ConclusionDespite the clear focus on longitudinal modelling and simulation in our search, we found very few examples of published PK or PK/PD models for the two case-studies considered, and almost no extrapolation approaches for paediatric or disease applications.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- stormTB: A web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatments. 91%
- Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan 90%
- Pharmacokinetics of caffeine: A systematic analysis of reported data for application in metabolic phenotyping and liver function testing 90%
Similar papers in this journal
- MTXPK.org: A clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase 90%
- DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19 89%
- Phenotypic models of drug-drug-gene interactions mediated by cytochrome drug-metabolizing enzymes 88%
Similar papers in this journal
- Preclinical Efficacy in Investigator’s Brochures: Stakeholders’ views on measures to improve Completeness and Robustness 91%
- Sensitivity of Estimated Tacrolimus Population Pharmacokinetic Profile to Inaccurate Assumptions about Dose Timing and Absorption: An Investigation in Real-World and Simulated Data 91%
- Investigation on the interaction between nifedipine and ritonavir containing antivirus regimens: a physiologically-based pharmacokinetic/pharmacodynamic analysis 88%
Similar papers in this journal
- Imbalanced Machine Learning Classification Models For Removal Biosimilar Drugs And Increased Activity In Patients With Rheumatic Diseases 93%
- Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses 92%
- Applying Historical Data in a Nonlinear Mixed-Effects Model Can Reduce the Number of Control Rats Required for Calculation of the Relative Potency of Insulin Analogues 92%
Similar papers in this journal
- Improved bioavailability of montelukast through a novel oral mucoadhesive film in humans and mice 90%
- A meta-analysis of in vitro release of hydrophilictherapeutics from contact lenses using mathematicalmodeling 90%
- Prediction of drug targets for specific diseases leveraging gene perturbation data: A machine learning approach 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.